ClinicalTrials.gov
ClinicalTrials.gov Menu

Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02864914
Recruitment Status : Active, not recruiting
First Posted : August 12, 2016
Last Update Posted : September 18, 2018
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
Empagliflozin (Jardiance), a highly potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), was approved in Europe in May 2014 for the treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic control in adults. As part of the risk management plan, Boehringer Ingelheim International GmbH (BI) has committed to conduct a post-authorisation safety study (PASS) to evaluate the liver and renal safety of empagliflozin. The study will also evaluate the risks of severe complications of urinary tract infections (UTIs) and genital infections. To evaluate the association between empagliflozin use and mentioned outcomes routinely collected health information from the Clinical Practice Research Datalink (CPRD), the Hospital Episodes Statistics, and Office of National Statistic will be used. This PASS will be conducted through an observational cohort study among adult patients with T2DM and at least 12 months of continuous enrolment in the CPRD where new users of empagliflozin will be compared to new users of dipeptidyl peptidase-4 (DPP4) inhibitors. Estimations will be made on the crude and adjusted incidence rates and adjusted incidence rate ratios of the primary and secondary outcomes.

Condition or disease Intervention/treatment
Diabetes Mellitus, Type 2 Drug: Empagliflozin Drug: DPP-4 inhibitors

Study Type : Observational
Actual Enrollment : 14800 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Post-authorisation Safety Study in Patients With Type 2 Diabetes Mellitus to Assess the Risk of Acute Liver Injury, Acute Kidney Injury and Chronic Kidney Disease, Severe Complications of Urinary Tract Infection, Genital Infections, and Diabetic Ketoacidosis Among Patients Treated With Empagliflozin Compared to Patients Treated With DPP-4 Inhibitors
Actual Study Start Date : March 15, 2016
Estimated Primary Completion Date : January 1, 2020
Estimated Study Completion Date : January 1, 2020

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Empagliflozin
Patients initiating Empagliflozin treatment within the study period
Drug: Empagliflozin
drug

DPP-4 inhibitors
Patients initiating DPP-4 inhibitor treatment within the study period
Drug: DPP-4 inhibitors
drug




Primary Outcome Measures :
  1. Incidence of acute liver injury (ALI) in patients with no predisposing conditions [ Time Frame: up to 5 years ]
  2. Acute kidney injury (AKI) [ Time Frame: up to 5 years ]
  3. Severe complications of urinary tract infections (UTIs) [ Time Frame: up to 5 years ]
  4. Genital infections [ Time Frame: up to 5 years ]
  5. Incidence of diabetic ketoacidosis (DKA) [ Time Frame: up to 5 years ]

Secondary Outcome Measures :
  1. Acute liver injury in patients with or without predisposing conditions [ Time Frame: up to 5 years ]
  2. Chronic kidney disease (CKD) [ Time Frame: up to 5 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
T2DM eligible patients in CPRD
Criteria

Inclusion criteria:

Patients will have T2DM, be initiating treatment with a study medication, and have at least 12 months of continuous registration in CPRD.

Exclusion criteria:

Patients will not have T1DM, will have no prior use of an SGLT2 inhibitor or DPP4 inhibitor, and will not be initiating a SGLT2-DPP4 fixed-dose combination. Additional different exclusion criteria will be applied according to each outcomes of interest.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02864914


Locations
United Kingdom
RTI health solutions
One Or Multiple Sites, United Kingdom
Sponsors and Collaborators
Boehringer Ingelheim
Eli Lilly and Company
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02864914     History of Changes
Other Study ID Numbers: 1245.96
First Posted: August 12, 2016    Key Record Dates
Last Update Posted: September 18, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Diabetic Ketoacidosis
Acidosis
Diabetes Mellitus
Diabetes Mellitus, Type 2
Ketosis
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Acid-Base Imbalance
Diabetes Complications
Empagliflozin
Dipeptidyl-Peptidase IV Inhibitors
Hypoglycemic Agents
Physiological Effects of Drugs
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action